Lactoferrin in Treatment of Fe Deficient Anemia In Cirrhosis

• Status: Recruiting
• Trial end date: 2022-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Iron deficiency and altered homeostasis due to inflammation and decreased iron utilization are main factors involved in anemia in liver disease. Lactoferrin is a first line defence protein for protection against microbial infections and subsequent development of systemic disease as seen with systemic inflammatory response syndrome (SIRS) and sepsis. Lactoferrin with iron has been shown to be efficacious with anemia in chronic disease, in pregnancy and in cancer patients with fewer side effects than oral iron alone. High exposure to iron is associated with increased inflammation which is associated with worse cardiovascular outcomes. Lactoferrin can help reduce the total iron dose and hepatic inflammation.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Postgraduate Institute of Medical Education and Research
• Treatments: Iron; Lactoferrin

Criteria

Inclusion Criteria:

1. Age 18-75 years

2. Either gender

3. Patients with chronic liver disease with iron deficiency anemia with transferrin saturation<20% and Hemoglobin in Non-pregnant women (15 years of age and above) <12g/dl and in men <13g/dl -

Exclusion Criteria:

1. Those who do not consent to participate in the study

2. Inability to obtain informed consent from patient or relatives

3. Severe preexisting cardiopulmonary disease

4. Renal dysfunction (S. Creatinine ≥ 2mg/dL)

5. Pregnancy/Lactation

6. Post liver transplant patients

7. HIV infection

8. Patients who are on psychoactive drugs, like sedatives or antidepressants

9. Patients who are too sick to carry out the protocol